(Q38187149)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Thomas Weichhart

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Klemens Budde

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Ignacio Duran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Peter-Jürgen Goebell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Konstantinos Papazisis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jose Antonio Rodriguez-Portal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

11 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

361-372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517115%20AND%20SRC:MED&resulttype=core&format=json

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Targeting mTOR in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Updates of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

An evaluation of sirolimus in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Comprehensive lung injury pathology induced by mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Pulmonary toxicities from targeted therapies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Mammalian target of rapamycin: Biological function and target for novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

The TSC-mTOR signaling pathway regulates the innate inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Regulation of immune responses by mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Severe everolimus-associated pneumonitis in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Pneumonitis Associated With Mammalian Target of Rapamycin Inhibitors in Renal Transplant Recipients: A Single-Center Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056

Toxicities of targeted therapy and their management in kidney cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.888056